Wide Ranks

BNOX

Bionomics Limited - American De

0.2980

Top Statistics
Market Cap 5 M Forward PE -0.1602 Revenue Growth 0.00 %
Current Ratio 3.45 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -51.59 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins 8909.69 %
Balance Sheet
Total Cash 12 M Total Cash Per Share 0.0040 Total Debt 239618
Total Debt To Equity 1.37 Current Ratio 3.45 Book Value Per Share 1.32
All Measures
Short Ratio 13.00 % Message Board Id finmb_3331473 Shares Short Prior Month 72985
Return On Equity -0.7844 City Eastwood Uuid 4e477dfa-aa36-3df0-8418-7ef77e024c33
Previous Close 0.2810 First Trade Date Epoch Utc 1 B Book Value 1.32
Beta -0.0690 Total Debt 239618 Volume 221398
Price To Book 0.2258 Fifty Two Week Low 0.1770 Total Cash Per Share 0.0040
Shares Short Previous Month Date 1 B Target Median Price 12.24 Max Age 86400
Recommendation Mean 1.67 Sand P52 Week Change 0.3133 Operating Margins 8909.69 %
Target Mean Price 15.37 Net Income To Common -15492166 Short Percent Of Float 0.0123
Implied Shares Outstanding 13 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 674300 Average Volume10days 674300 Total Cash 12 M
Next Fiscal Year End 1 B Held Percent Insiders 0.3391 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.2810
Target Low Price 6.13 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.3408
Open 0.2829 Free Cashflow -7925286 State SA
Dividend Yield 0.00 % Return On Assets -0.3958 Time Zone Short Name EST
Trailing Eps -1.19 Day Low 0.2746 Address1 200 Greenhill Road
Shares Outstanding 19 M Price Hint 4 Target High Price 27.73
Website https://www.bionomics.com.au 52 Week Change -0.7742 Average Volume 9 M
Forward Eps -1.86 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 332.60 % Is_sp_500 False Regular Market Day High 0.2980
Profit Margins 0.00 % Debt To Equity 1.37 Fifty Two Week High 1.60
Day High 0.2980 Shares Short 190271 Regular Market Open 0.2829
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0110 Operating Cashflow -14680777 Currency USD
Time Zone Full Name America/New_York Market Cap 5 M Is_nasdaq_100 False
Zip 5063 Quote Type EQUITY Industry Biotechnology
Long Name Bionomics Limited Regular Market Day Low 0.2746 Held Percent Institutions 0.1622
Current Price 0.2980 Enterprise To Ebitda -51.59 Financial Currency USD
Current Ratio 3.45 Industry Disp Biotechnology Number Of Analyst Opinions 3
Country Australia Float Shares 2 B Two Hundred Day Average 0.7327
Ir Website http://www.bionomics.com.au/page.php?section=34 Enterprise Value 895 M Forward PE -0.1602
Regular Market Volume 221398 Ebitda -17351144 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.

Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder.

The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.

1/3.

2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.

7/1.

8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment.

The company has a collaboration with Merck & Co.

, Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions.

Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.